» Articles » PMID: 38069310

Albumin-Based Liver Reserve Models Vs. MELD 3.0 in Prognostic Prediction for Hepatocellular Carcinoma Patients with Renal Insufficiency

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Dec 9
PMID 38069310
Authors
Affiliations
Soon will be listed here.
Abstract

The severity of liver functional reserve is an important prognostic predictor in hepatocellular carcinoma (HCC). The albumin-bilirubin (ALBI), easy (EZ)-ALBI, platelet-albumin-bilirubin (PALBI), platelet-albumin (PAL) score, and MELD 3.0 score are used to evaluate the severity of liver dysfunction. However, their prognostic role in HCC patients, specifically with renal insufficiency (RI), is unclear. We aimed to investigate the predictive accuracy of the five models in these patients. A total of 1120 newly diagnosed HCC patients with RI were enrolled. A multivariate Cox proportional analysis was used to identify independent predictors associated with survival. In the Cox model, older age, an α-fetoprotein ≥20 ng/mL, vascular invasion, a medium and high tumor burden score, poor performance status, a higher ALBI grade, an EZ-ALBI grade, a PALBI grade, a PAL grade, and MELD 3.0 score were all independently associated with decreased overall survival (all < 0.001). Among the five liver reserve models, the ALBI grade is the best surrogate marker to represent liver functional reserve in terms of outcome prediction. The albumin-based liver reserve models (ALBI, EZ-ALBI, PALBI, and PAL) and MELD 3.0 are all feasible prognostic markers to indicate liver injury, specifically in HCC patients with RI. Among them, the ALBI grade is the most robust tool for survival prediction in these patients.

Citing Articles

Prognostic value of albumin-bilirubin grade in patients with cholangiocarcinoma: a systematic review and meta-analysis.

Omouri-Kharashtomi M, Alemohammad S, Moazed N, Afzali Nezhad I, Ghoshouni H BMC Gastroenterol. 2025; 25(1):19.

PMID: 39815213 PMC: 11736951. DOI: 10.1186/s12876-025-03596-6.


The Development and Appraisal of MELD 3.0 in Liver Diseases: Good Things Never Come Easy.

Guo G, Yang W, Li J, Yang Z, Liang J, Sun C J Clin Transl Hepatol. 2025; 13(1):62-68.

PMID: 39801783 PMC: 11712091. DOI: 10.14218/JCTH.2024.00303.


Construction of an interpretable model for predicting survival outcomes in patients with middle to advanced hepatocellular carcinoma (≥5 cm) using lasso-cox regression.

Li H, Yang B, Wang C, Li B, Han L, Jiang Y Front Pharmacol. 2024; 15:1452201.

PMID: 39372198 PMC: 11450703. DOI: 10.3389/fphar.2024.1452201.

References
1.
Levin A, Stevens P . Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2013; 85(1):49-61. DOI: 10.1038/ki.2013.444. View

2.
Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K . Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. Liver Cancer. 2019; 8(2):121-129. PMC: 6465715. DOI: 10.1159/000488778. View

3.
Liu R, Li R, Zhang M, Liu W, Li H, Li D . Prognostic Value of Platelet-Albumin-Bilirubin Grade in Child-Pugh A and B Patients With Hepatocellular Carcinoma: A Meta-Analysis. Front Oncol. 2022; 12:914997. PMC: 9326061. DOI: 10.3389/fonc.2022.914997. View

4.
Kim W, Mannalithara A, Heimbach J, Kamath P, Asrani S, Biggins S . MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021; 161(6):1887-1895.e4. PMC: 8608337. DOI: 10.1053/j.gastro.2021.08.050. View

5.
Shindoh J, Kawamura Y, Kobayashi Y, Kiya Y, Sugawara T, Akuta N . Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients with Hepatocellular Carcinoma. J Gastrointest Surg. 2018; 23(1):76-83. DOI: 10.1007/s11605-018-3871-1. View